Vaxcyte, Inc. 4

EVP/COO Jim Wassil executed Rule 10b5-1 sales and an RSU tax-withholding share surrender in Vaxcyte, Inc. common stock totaling 8,174 shares over three days in early September 2026.

On this Form 4, Jim Wassil, EVP, Chief Scientific Officer and COO of Vaxcyte, Inc., reported three transactions in Vaxcyte common stock. On 2026-09-04, he sold 1,381 shares at a weighted-average price of $61.16 per share under a Rule 10b5-1 trading plan, for proceeds of approximately $84,500. On 2026-09-08, 5,459 shares were surrendered to the issuer at a price of $60.36 per share to cover tax withholding obligations related to the vesting of RSUs, a non-discretionary, compensation-related transaction valued at about $329,500. On 2026-09-09, he sold an additional 1,334 shares at a weighted-average price of $59.521 per share, for proceeds of roughly $79,400. Following these transactions, Wassil held 145,435 shares of Vaxcyte common stock, representing an equity position with an estimated value of approximately $8.65 million based on the prevailing transaction price context.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001813798-26-000019

Alert Tier

6